Sep 8, 2026 08:00AM
Aug 13, 2026 08:00AM
Aug 13, 2026 08:00AM
Aug 11, 2026 05:21PM
Jul 13, 2026 04:06PM
Jul 13, 2026 04:05PM
Jul 7, 2026 08:02AM Eupraxia Pharmaceuticals adds three directors to its board
Jul 7, 2026 08:00AM
Jun 19, 2026 04:02PM
May 28, 2026 08:00AM
May 12, 2026 05:00PM
May 6, 2026 07:00AM
May 6, 2026 07:00AM
May 5, 2026 07:00AM Eupraxia reports trial data showing dose-related improvements in esophagitis
May 5, 2026 07:00AM
May 1, 2026 05:05PM
May 1, 2026 05:05PM
Apr 22, 2026 07:00AM
Apr 21, 2026 07:00AM
Apr 21, 2026 07:00AM
Apr 13, 2026 08:00AM Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
Mar 17, 2026 07:00AM
Mar 17, 2026 07:00AM
Mar 12, 2026 09:03PM
Jan 8, 2026 07:34AM
Jan 8, 2026 07:34AM
Nov 13, 2025 05:00PM
Nov 13, 2025 05:00PM Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI
Nov 4, 2025 04:39PM
Sep 29, 2025 05:00PM
Sep 29, 2025 05:00PM
Sep 2, 2025 08:02AM
Sep 2, 2025 08:00AM
Sep 2, 2025 08:00AM
Aug 12, 2025 04:25PM Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 22, 2025 05:17PM
Jul 8, 2025 07:00AM
Jul 8, 2025 07:00AM
Jun 2, 2025 06:30PM
May 7, 2025 02:00PM
May 6, 2025 06:00PM
May 5, 2025 07:00AM Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI
Apr 24, 2025 05:00PM
Mar 20, 2025 05:32PM
Feb 25, 2025 07:01AM
Feb 25, 2025 07:00AM
Feb 18, 2025 07:00AM
Feb 18, 2025 07:00AM
Nov 20, 2024 07:00AM Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Nov 14, 2024 05:00PM

330,674 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All